One of Eli Lilly’s most promising new obesity drugs helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis. The drug giant’s LLY stock was ...

(REUTERS) — Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial, outperforming its blockbuster drug Zepbound and ...

Eli Lilly (LLY) shares spiked ~3% on Thursday after the obesity drugmaker posted Phase 3 data showing its next-gen therapy retatrutide can generate up to 24% of weight loss, a “best-in-class" efficacy ...

A new weight-loss drug that Eli Lilly is testing is helping patients in a late-stage trial lose an average of 28.7% of their body weight and offered "substantial" relief from osteoarthritis pain. In ...

Patients on Eli Lilly’s next-generation obesity shot lost nearly 30% of their body weight on average in a trial that tracked them for a little more than a year—a result that’s far better than the most ...

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. The ...

Eli Lilly LLY0.50%increase; green up pointing triangle said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, ...

Eli Lilly has unveiled a new weight loss drug that appears to be delivering the highest weight loss yet in clinical trials while at the same time reducing knee arthritis pain. Participants on ...

An Eli Lilly drug candidate designed to hit three metabolic targets led patients to lose an average of 28.7% of their body weight in a late-stage clinical trial, setting a new high mark in the ...

Eli Lilly (LLY) announced on Thursday that a late-stage trial for its next-generation weight loss candidate, retatrutide, met all primary and key secondary endpoints in obese or overweight adults with ...